P
Protembis
Protembis is a medical device start-up company developing Cerebral Protection System
About Protembis
Protembis is a medical device company that has developed the ProtEMBisa, an intra-aortic cerebral protection device designed to minimize the risk of stroke and other neurological injuries during transcatheter aortic valve replacement (TAVR) procedures.
The company's core product is a catheter-based system that is inserted through the radial artery in the wrist and positioned in the aorta to deflect embolic debris away from the brain. This addresses a significant unmet need in the rapidly growing TAVR market, where stroke is a major complication.
Protembis' business model is focused on the development and commercialization of this proprietary technology. The company generates revenue through the sale of its cerebral protection device to hospitals and cardiac centers that perform TAVR procedures. Its primary customers are interventional cardiologists and cardiac surgeons.
The company has raised a total of $42.5M in funding over 5 rounds from 13 investors, which has supported the development and clinical testing of its device. Protembis is headquartered in Aachen, Germany, and operates in the medical device sector, specifically within the cardiovascular and neurovascular markets.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Aachen, Germany
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 66.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Risk Management, Neurology, Sustainable Development Goals, Hard Tech, start2 group, German Accelerator
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Jul 2024 | $22M | — | European Investment Bank | ↗ |
| SERIES B✓Equity / VC | Mar 2024 | $33M | $132M | TechVision Fonds · Coparion · Segulah Medical · XGEN Venture | ↗ |
Growth signals
Latest recorded traffic for Protembis is 200 monthly website visits, down 4.8% over the last three months. Protembis's team declined 17.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
IFB Innovationsstarter
Series A6 investors entered at this stage
Coparion
Seed Fonds Aachen
Abiomed
TechVision Fonds
Segulah Medical
XGEN Venture
Series B and later1 investor entered at this stage
European Investment Bank
Other known investors1 additional known investor
German Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protembis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protembis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.